MindMed Announces Chief Executive Officer Transition
News provided by
Share this article
Share this article
NEW YORK, June 9, 2021 /PRNewswire/ Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the Company ), a leading clinical-stage pharmaceutical company and pioneer in the field of psychedelic inspired medicines, announces that J.R. Rahn, the Company s co-founder and chief executive officer, is stepping down as chief executive officer and a director, and that its chief development officer, Robert Barrow, will assume the position of chief executive officer with immediate effect. The Company will also initiate a comprehensive search for a chief executive officer, in which Mr. Barrow will be a candidate, and Mr. Rahn will advise the Company during its leadership transition. The transition of the Company s leadership team will enable the Company to pursue aggressively its clinical development programs and development of its companion innovative digital techno
Psychedelic drugmaker MindMed stumbles in Nasdaq debut, CEO says still very early innings
yahoo.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from yahoo.com Daily Mail and Mail on Sunday newspapers.
Kašlete na svůj telefon, vyzývají vědci Čechy A myslí to doslova, do klinické studie kašle se může zapojit každý
euro.cz - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from euro.cz Daily Mail and Mail on Sunday newspapers.
Field Trip Intends to Use the Net Proceeds From the Offering for the Development of the Company’s FT-104 Novel Psychedelic Development Program, the Opening of New Field Trip Health Centers, and for Working Capital and General Corporate Purposes
Field Trip Health (OTC:FTRPF) announced that, due to strong demand, it has agreed with a syndicate of underwriters led by Bloom Burton Securities, to increase the size of its previously announced $50,000,015 bought deal offering. Pursuant to the upsized deal terms, the underwriters have agreed to purchase, on a bought deal basis, 12,750,000 common shares of Field Trip, at a price of $6.50, for aggregate gross proceeds of $82,875,000.
Psychedelic Stocks Poised to Resume the Upward Trend
News Provided By
Share This Article
Fears of inflation and higher interest rates roiled the market for growth stocks, but the long-term prospects for psychedelic medicine remains bullish
/EIN News/ ATLANTA, Feb. 25, 2021 (GLOBE NEWSWIRE) Fears of inflation and higher interest rates sent the NASDAQ Composite and Russell 2000 lower the past few weeks as many investors ran for cover. Almost as if on command, the same market pundits who were bullish prior to the correction suddenly voiced public concern about the valuations on psychedelic stocks. What they fail to remember is, growth stocks, like those in the psychedelic sector, are almost always considered overpriced by traditional analysis.